Regarding HDAC inhibitors, a phase I clinical and pharmacokinetic trial study of vorinostat has been conducted in individuals with solid tumors including NB and was found to exhibit a maximum tolerated dose of 230 mg/m2/day.286. Here, HDAC9 is linked to neuroblastoma.